Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMHCNASDAQ:AVXLNASDAQ:REPLNASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMHCAmplitude Healthcare Acquisition$15.12$11.82$9.80▼$15.80$189M0.11128,744 shs2.25 million shsAVXLAnavex Life Sciences$7.53-1.8%$8.75$3.51▼$14.44$642.85M0.821.23 million shs666,574 shsREPLReplimune Group$8.35-4.7%$8.63$4.92▼$17.00$643.08M0.68927,781 shs1.46 million shsTSHATaysha Gene Therapies$2.75-3.5%$1.83$1.05▼$4.32$590.32M0.92.91 million shs4.06 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMHCAmplitude Healthcare Acquisition0.00%0.00%0.00%0.00%0.00%AVXLAnavex Life Sciences0.00%-9.50%-20.32%-9.82%+67.33%REPLReplimune Group0.00%+6.37%-7.84%-40.27%+40.81%TSHATaysha Gene Therapies0.00%+1.85%+51.10%+70.81%-7.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMHCAmplitude Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAVXLAnavex Life Sciences3.7544 of 5 stars3.71.00.04.72.80.80.6REPLReplimune Group3.8267 of 5 stars3.60.00.04.53.02.50.6TSHATaysha Gene Therapies2.9158 of 5 stars4.50.00.00.02.91.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMHCAmplitude Healthcare Acquisition 0.00N/AN/AN/AAVXLAnavex Life Sciences 3.33Buy$44.00484.33% UpsideREPLReplimune Group 3.13Buy$19.43132.68% UpsideTSHATaysha Gene Therapies 3.00Buy$6.57138.96% UpsideCurrent Analyst Ratings BreakdownLatest AMHC, REPL, AVXL, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025TSHATaysha Gene TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.004/28/2025TSHATaysha Gene TherapiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.004/28/2025TSHATaysha Gene TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.004/10/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.002/27/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/26/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.002/26/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMHCAmplitude Healthcare AcquisitionN/AN/AN/AN/A$0.40 per shareN/AAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/ATSHATaysha Gene Therapies$7.22M81.72N/AN/A$0.40 per share6.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMHCAmplitude Healthcare Acquisition-$590KN/A0.00∞N/AN/A66.84%3.31%N/AAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%8/6/2025 (Estimated)TSHATaysha Gene Therapies-$111.57M-$0.344.37N/AN/A-229.67%-106.36%-49.16%8/11/2025 (Estimated)Latest AMHC, REPL, AVXL, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/A5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A2/26/2025Q4 2024TSHATaysha Gene Therapies-$0.08-$0.07+$0.01-$0.07$2.05 million$2.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMHCAmplitude Healthcare AcquisitionN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMHCAmplitude Healthcare AcquisitionN/A1.291.29AVXLAnavex Life SciencesN/A9.459.45REPLReplimune Group0.1411.4311.43TSHATaysha Gene Therapies0.485.515.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMHCAmplitude Healthcare Acquisition67.87%AVXLAnavex Life Sciences31.55%REPLReplimune Group92.53%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipAMHCAmplitude Healthcare AcquisitionN/AAVXLAnavex Life Sciences11.40%REPLReplimune Group8.80%TSHATaysha Gene Therapies2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMHCAmplitude Healthcare Acquisition312.50 millionN/ANot OptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableREPLReplimune Group21077.02 million70.24 millionOptionableTSHATaysha Gene Therapies180214.66 million199.41 millionOptionableAMHC, REPL, AVXL, and TSHA HeadlinesRecent News About These CompaniesFY2025 EPS Estimates for TSHA Increased by Cantor FitzgeraldMay 23 at 8:29 AM | marketbeat.comCantor Fitzgerald Has Positive View of TSHA FY2025 EarningsMay 23 at 2:43 AM | americanbankingnews.comVR Adviser LLC Sells 5,774,820 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 22 at 6:53 AM | marketbeat.comRTW Investments LP Has $15 Million Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 18, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.1% Following Analyst UpgradeMay 17, 2025 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comQ1 2025 Taysha Gene Therapies Inc Earnings CallMay 16, 2025 | finance.yahoo.comTaysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ...May 16, 2025 | finance.yahoo.comTaysha Gene Therapies Advances in Rett Syndrome TrialsMay 16, 2025 | tipranks.comTaysha outlines expedited pivotal trial start for TSHA-102 following FDA alignmentMay 15, 2025 | msn.comTaysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2025 | zacks.comTaysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | globenewswire.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Bought by Octagon Capital Advisors LPMay 15, 2025 | marketbeat.comGranahan Investment Management LLC Buys 496,482 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 13, 2025 | marketbeat.comDAFNA Capital Management LLC Makes New $904,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 10, 2025 | marketbeat.comTaysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15May 8, 2025 | globenewswire.comTaysha Gene Therapies (TSHA) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comMarshall Wace LLP Lowers Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)May 8, 2025 | marketbeat.comWill Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should KnowMay 6, 2025 | zacks.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 9.3% - What's Next?May 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMHC, REPL, AVXL, and TSHA Company DescriptionsAmplitude Healthcare Acquisition NASDAQ:AMHCAmplitude Healthcare Acquisition Corporation does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to focus on the life sciences and pharmaceutical services sectors in the United States and Europe. Amplitude Healthcare Acquisition Corporation was incorporated in 2019 and is based in New York, New York.Anavex Life Sciences NASDAQ:AVXL$7.53 -0.14 (-1.83%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.54 +0.00 (+0.07%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Replimune Group NASDAQ:REPL$8.35 -0.41 (-4.68%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.65 +0.30 (+3.59%) As of 05/23/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Taysha Gene Therapies NASDAQ:TSHA$2.75 -0.10 (-3.51%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.75 0.00 (0.00%) As of 05/23/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
